Apellis Pharmaceuticals Cash from Financing (TTM) Analysis

Apellis Pharmaceuticals Inc (APLS)

47.51 -0.52 (-1.08%) USD | NASDAQ | Apr 18, 16:00

47.50 -0.01 (-0.02%) After-Hours: 20:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2018. Upgrade now.

Date	Value
December 31, 2023	394.50M
September 30, 2023	382.47M
June 30, 2023	386.36M
March 31, 2023	380.06M
December 31, 2022	365.66M
September 30, 2022	765.56M
June 30, 2022	758.05M
March 31, 2022	767.31M
December 31, 2021	392.24M
September 30, 2021	14.60M
June 30, 2021	13.40M
March 31, 2021	290.54M

Date	Value
December 31, 2020	692.18M
September 30, 2020	686.07M
June 30, 2020	884.09M
March 31, 2020	643.39M
December 31, 2019	388.54M
September 30, 2019	388.45M
June 30, 2019	189.46M
March 31, 2019	280.10M
December 31, 2018	131.90M
September 30, 2018	309.83M
June 30, 2018	329.20M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

13.40M

Minimum

Jun 2021

884.09M

Maximum

Jun 2020

462.26M

Average

388.54M

Median

Dec 2019

Cash from Financing (TTM) Benchmarks